Innovation Pharmaceuticals Stock Analysis
| IPIX Stock | USD 0.0009 0.0007 350.00% |
Innovation Pharmaceuticals holds a debt-to-equity ratio of 0.361. With a high degree of financial leverage come high-interest payments, which usually reduce Innovation Pharmaceuticals' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Innovation Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Innovation Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Innovation Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Innovation Pharmaceuticals' stakeholders.
For most companies, including Innovation Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Innovation Pharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Innovation Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Innovation Pharmaceuticals' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Innovation Pharmaceuticals is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Innovation Pharmaceuticals to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Innovation Pharmaceuticals is said to be less leveraged. If creditors hold a majority of Innovation Pharmaceuticals' assets, the Company is said to be highly leveraged.
Innovation Pharmaceuticals is overvalued with Real Value of 8.44E-4 and Hype Value of 8.2E-4. The main objective of Innovation Pharmaceuticals pink sheet analysis is to determine its intrinsic value, which is an estimate of what Innovation Pharmaceuticals is worth, separate from its market price. There are two main types of Innovation Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Innovation Pharmaceuticals pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Innovation |
Innovation Pink Sheet Analysis Notes
The book value of the company was currently reported as 0.01. The company recorded a loss per share of 0.02. Innovation Pharmaceuticals had not issued any dividends in recent years. Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts. Innovation Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.The quote for Innovation Pharmaceuticals is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Innovation Pharmaceuticals call Leo CPA at 978 921 4125 or check out https://www.ipharminc.com.Innovation Pharmaceuticals Investment Alerts
| Innovation Pharmaceuticals is way too risky over 90 days horizon | |
| Innovation Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Innovation Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Innovation Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Innovation Pharmaceuticals currently holds 1.24 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Innovation Pharmaceuticals has a current ratio of 0.59, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation to invest in growth at high rates of return. When we think about Innovation Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 18 K. Net Loss for the year was (7.04 M) with profit before overhead, payroll, taxes, and interest of 18 K. | |
| Innovation Pharmaceuticals currently holds about 2.97 M in cash with (6.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from fool.com: Dividend Growers 2 Stocks That Could Be Worth 1 Trillion in 7 Years |
Innovation Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Innovation Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Innovation Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 1st of February, Innovation Pharmaceuticals retains the Market Risk Adjusted Performance of (0.89), risk adjusted performance of 0.1233, and Downside Deviation of 37.16. Innovation Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Innovation Pharmaceuticals Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Innovation Pharmaceuticals price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
Innovation Pharmaceuticals Outstanding Bonds
Innovation Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Innovation Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Innovation bonds can be classified according to their maturity, which is the date when Innovation Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Installed Building Products Corp BondUS45780RAA95 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Innovation Pharmaceuticals Predictive Daily Indicators
Innovation Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Innovation Pharmaceuticals pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Innovation Pharmaceuticals Forecast Models
Innovation Pharmaceuticals' time-series forecasting models are one of many Innovation Pharmaceuticals' pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Innovation Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Innovation Pharmaceuticals Debt to Cash Allocation
Innovation Pharmaceuticals currently holds 1.24 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Innovation Pharmaceuticals has a current ratio of 0.59, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation to invest in growth at high rates of return. When we think about Innovation Pharmaceuticals' use of debt, we should always consider it together with cash and equity.Innovation Pharmaceuticals Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Innovation Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Innovation Pharmaceuticals, which in turn will lower the firm's financial flexibility.Innovation Pharmaceuticals Corporate Bonds Issued
About Innovation Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Innovation Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Innovation shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Innovation Pharmaceuticals. By using and applying Innovation Pink Sheet analysis, traders can create a robust methodology for identifying Innovation entry and exit points for their positions.
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts. Innovation Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Innovation Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
| All Next | Launch Module |
Additional Tools for Innovation Pink Sheet Analysis
When running Innovation Pharmaceuticals' price analysis, check to measure Innovation Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation Pharmaceuticals is operating at the current time. Most of Innovation Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Innovation Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation Pharmaceuticals' price. Additionally, you may evaluate how the addition of Innovation Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.